Key result
Trimetazidine improves LVEF by ~13% vs control in breast cancer patients on anthracycline chemotherapy.
Why the study?
Anthracycline-induced cardiotoxicity causes chronic cardiovascular complications and reduces long-term survival in breast cancer patients, requiring systematic evaluation of cardioprotective pharmacological agents.
Do pharmacological cardioprotective agents prevent anthracycline-induced cardiotoxicity in female breast cancer patients?
Meta-Analysis (n=2,599)
Do pharmacological cardioprotective agents prevent anthracycline-induced cardiotoxicity in female breast cancer patients?
Trimetazidine, ACEI/ARB, beta-blockers, dexrazoxane, and MRAs show distinct, specific cardioprotective benefits against anthracycline-induced cardiotoxicity in breast cancer patients.
Answers are grounded in this paper and cite their sources.
Trimetazidine supports LVEF preservation during anthracycline therapy; extends meta-analytic evidence for metabolic cardioprotection in breast cancer.
INTRODUCTION: Anthracycline-induced cardiotoxicity is a significant concern for breast cancer patients undergoing treatment, often leading to chronic cardiovascular complications and reduced long-term survival. The study aimed to systematically evaluate the efficacy of nine classes of pharmacological agents in protecting against cardiotoxicity in breast cancer patients treated with anthracyclines. METHODS: A comprehensive search of databases was performed from January 2000 to October 2024 to identify randomized controlled trials (RCTs) investigating cardioprotective agents. The risk of bias in the studies was evaluated using the Cochrane risk-of-bias tool. Bayesian network meta-analysis was conducted in Stata 15.1. RESULTS: Of 3718 studies identified, 29 RCTs involving 2599 patients were included in the network systematic review. The study found that trimetazidine significantly improved left ventricular ejection fraction (LVEF), with a Surface Under the Cumulative Ranking (SUCRA) of 94.0%. The combination of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker with beta-blocker (AA-BB) significantly improved global longitudinal strain (GLS), with a SUCRA of 72.8%. Dexrazoxane was highly effective, significantly reducing B-type natriuretic peptide (BNP) levels, cardiac troponin (cTn) levels, and the E/e' ratio (ratio of the mitral early filling velocity to the mean early relaxation tissue velocity), with SUCRA values of 98.9%, 98.2%, and 99.9%, respectively. Additionally, mineralocorticoid receptor antagonist (MRA) showed the highest SUCRA of 88.4% for improving the E/A ratio (ratio of the mitral early diastolic velocity to the late diastolic velocity). DISCUSSION: Trimetazidine, ACEI/ARB, beta-blocker, dexrazoxane, and MRA demonstrate potential as cardioprotective agents in breast cancer patients undergoing anthracycline chemotherapy. Further research is needed to elucidate the specific cardioprotective mechanisms against anthracycline-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) conducted a meta-analysis in Anthracycline-induced cardiotoxicity in breast cancer (n=2,599). Cardioprotective agents (trimetazidine, ACEI/ARB, beta-blockers, dexrazoxane, MRA) vs. Placebo or no treatment was evaluated on Left ventricular ejection fraction (LVEF) (MD 12.94, 95% CI 2.22-23.67). Trimetazidine improved left ventricular ejection fraction compared to control in breast cancer patients undergoing anthracycline chemotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: